FDA approves FET-PET agent for glioma
The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.
-
By
-
Kathryn Wighton
-
September 14, 2026
-
Clinical Scorecard: FDA approves FET-PET agent for glioma
At a Glance
| Category | Detail |
|---|
| Condition | Glioma |
| Key Mechanisms | Targets L-type amino acid transporters 1 and 2 for PET imaging. |
| Target Population | Adult and pediatric patients aged 1 month or older. |
| Care Setting | Positron emission tomography imaging. |
Key Highlights
- Remove or source the claim about safety evaluated in 382 patients.
Guideline-Based Recommendations
Diagnosis
- FET-PET imaging is recommended for differentiating recurrent or progressive glioma from treatment-related changes.
Management
- Interpretation of PET results should incorporate histopathology, cross-sectional imaging, and clinical history.
Monitoring & Follow-up
- Monitor for potential side effects such as headache, nausea, and injection-site reactions.
Risks
- Cumulative radiation exposure associated with increased risk of cancer.
Patient & Prescribing Data
Patients with gliomas, including adults and pediatric patients.
Floretyrosine F 18 is administered intravenously and allows PET detection of emitted energy.
Clinical Best Practices
- Use FET-PET imaging in conjunction with other diagnostic modalities.
- Be aware of the potential for false-positive or false-negative interpretations.
Related Resources & Content
